Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 0.52 |
| ▸ | HTR2A | P28223 | 16/20 | 0.52 |
| ▸ | DRD3 | P35462 | 16/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7243612 | 0.84 | SIGMAR1 (0.47) | DRD2HTR2ADRD3OPRM1OPRK1 | |
| SCHEMBL7242535 | 0.79 | SIGMAR1 (0.52) | DRD2HTR2ADRD3OPRM1OPRK1 | |
| SCHEMBL7243853 | 0.79 | DRD2 (0.48) | DRD2HTR2ADRD3OPRM1OPRK1 | |
| SCHEMBL7243095 | 0.77 | SIGMAR1 (0.71) | SIGMAR1 | |
| SCHEMBL7242622 | 0.77 | DRD2 (0.50) | DRD2HTR2ADRD3OPRM1OPRK1 | |
| SCHEMBL7243177 | 0.76 | DRD2 (0.47) | DRD2HTR2ADRD3OPRM1OPRK1 | |
| SCHEMBL7243547 | 0.73 | SIGMAR1 (0.51) | DRD2HTR2ADRD3SIGMAR1 | |
| SCHEMBL7242874 | 0.73 | DRD2 (0.45) | DRD2HTR2ADRD3OPRM1OPRK1 | |
| SCHEMBL7242868 | 0.73 | DRD2 (0.45) | DRD2HTR2ADRD3OPRM1OPRK1 | |
| SCHEMBL7243042 | 0.73 | DRD2 (0.50) | DRD2HTR2ADRD3OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171413-A1 | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders | CELLTECH R & D LIMITED (GB) | 2003-09-11 | — | — | US | claimed |
| EP-1311502-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | Celltech R&D Limited (GB) | 2003-05-21 | — | — | EP | claimed |
| WO-2002016353-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CELLTECH R & D LIMITED (GB) | 2002-02-28 | — | — | WO | claimed |
| US-20030171413-A1 | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders | CELLTECH R & D LIMITED (GB) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171413-A1 | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders | CCR1, CCR3, CCRL2 | DRD2 1053/4885HTR2A 2663/4885DRD3 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.